僵直性脊椎炎市場規模、佔有率和成長分析（按藥物類別、分銷管道和地區分類）—產業預測（2026-2033 年）

預計到 2024 年，全球僵直性脊椎炎市場規模將達到 72.8 億美元，到 2025 年將達到 78.2 億美元，到 2033 年將達到 138.4 億美元，預測期（2026-2033 年）的複合年成長率為 7.4%。

全球僵直性脊椎炎市場正經歷顯著成長，其促進因素包括影響這種影響脊椎和關節的慢性發炎性疾病的診斷、治療和管理。主要促進因素包括疾病盛行率和公眾意識的提高，從而推動了診斷方法的改進和早期發現。此外，醫學研究的進步和新型治療方法的出現拓寬了治療選擇，使其對更容易患此病的老年人尤為具有吸引力。有效的藥物，例如非類固醇消炎劑(NSAIDs) 和生物製藥（包括 TNF 抑制劑），提高了患者的生活品質，從而刺激了市場需求。然而，由於症狀不典型，診斷具有挑戰性，導致治療費用高昂、醫療資源有限，並且由於缺乏根治性治療方法，患者需要持續進行疾病管理。

全球僵直性脊椎炎市場促進因素

全球僵直性脊椎炎市場正經歷成長，這主要得益於醫學研究的重大進展，這些進展加深了我們對該疾病及其機制的理解。包括腫瘤壞死因子 (TNF) 抑制劑和白細胞介素抑制劑在內的創新標靶治療的引入，徹底改變了僵直性脊椎炎的治療方式，為患者提供了更有效的治療選擇。此外，治療指引的不斷改進以及這些強效藥物的日益普及，也推動了患者預後的改善。這些因素共同促進了對這種慢性疾病更全面的管理，並支撐著僵直性脊椎炎治療市場的擴張。

限制全球僵直性脊椎炎市場的因素

由於僵直性脊椎炎需要長期管理和持續治療，全球僵直性脊椎炎市場面臨一定的限制因素。有效的疾病管理高度依賴患者對處方藥物的依從性、生活方式的調整以及定期追蹤。這些因素帶來了許多挑戰，例如如何維持患者的用藥依從性和調整日常習慣，最終可能影響市場整體成長。此外，疾病後續觀察的複雜性也構成了額外的障礙，凸顯了為僵直性脊椎炎患者提供持續支持和幫助的必要性。

全球僵直性脊椎炎市場趨勢

全球僵直性脊椎炎市場正呈現出一股顯著的趨勢，即優先考慮早期診斷和治療，因為人們越來越認知到早期診斷和治療對患者預後的影響。醫療服務提供者和患者權益倡導組織對僵直性脊椎炎的認知不斷提高，促使更多教育活動強調早期發現和介入的重要性。這種積極主動的方法使醫療專業人員能夠及時啟動適當的治療，有效控制炎症，並延緩疾病進展。這一趨勢可望推動對先進診斷工具和創新治療方案的需求，最終有助於提高患者的生活品質，並擴大市場機會。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球僵直性脊椎炎市場規模（按藥物類別和複合年成長率分類）（2026-2033 年）

• 非類固醇消炎劑（NSAIDs）
• TNF抑制劑
  • 修美樂
  • 辛波尼
  • Remicade
  • Enbrel
  • Cimzia
  • 其他TNF抑制劑
• 其他藥物類別

全球僵直性脊椎炎市場規模（依分銷管道分類）及複合年成長率（2026-2033 年）

• 醫院藥房
• 零售藥房
• 其他

全球僵直性脊椎炎市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• AbbVie Inc.（United States）
• Amgen Inc.（United States）
• Pfizer Inc.（United States）
• Johnson & Johnson（United States）
• Novartis AG（Switzerland）
• UCB SA（Belgium）
• Eli Lilly and Company（United States）
• Merck & Co., Inc.（United States）
• Boehringer Ingelheim International GmbH（Germany）
• Gilead Sciences Inc.（United States）
• Bristol-Myers Squibb Company（United States）
• AstraZeneca plc（United Kingdom）
• Sanofi SA（France）
• GlaxoSmithKline plc（United Kingdom）
• Horizon Therapeutics plc（Ireland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sandoz International GmbH（Germany）
• Zydus Lifesciences Limited（India）
• Izana Bioscience（United Kingdom）

結論與建議

Global Ankylosing Spondylitis Market size was valued at USD 7.28 Billion in 2024 and is poised to grow from USD 7.82 Billion in 2025 to USD 13.84 Billion by 2033, growing at a CAGR of 7.4% during the forecast period (2026-2033).

The global ankylosing spondylitis market is witnessing remarkable growth fueled by factors influencing diagnosis, treatment, and management of this chronic inflammatory disease affecting the spine and joints. Key drivers include a rising prevalence of the condition and heightened awareness, leading to earlier detection due to improved diagnostic methods. Moreover, advancements in medical research and novel therapies have broadened treatment options, appealing particularly to the aging population that is more susceptible to the disease. Effective medications, such as NSAIDs and biologics like TNF inhibitors, enhance patient quality of life, increasing market demand. Nonetheless, challenges remain, including underdiagnosis due to vague symptoms, high treatment costs, limited healthcare access, and the necessity for continuous disease management without a definitive cure.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ankylosing Spondylitis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ankylosing Spondylitis Market Segments Analysis

Global Ankylosing Spondylitis Market is segmented by Drug Class, Distribution Channel and region. Based on Drug Class, the market is segmented into Non-Steroidal Anti Inflammatory Drug (NSAID), TNF Inhibitors and Other Drug Classes. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Ankylosing Spondylitis Market

The Global Ankylosing Spondylitis market is experiencing growth driven by significant advancements in medical research that have enhanced the understanding of the disease and its mechanisms. The introduction of innovative targeted therapies, including tumor necrosis factor (TNF) inhibitors and interleukin inhibitors, has transformed the management of ankylosing spondylitis, offering patients more effective treatment options. Furthermore, the continuous development of treatment guidelines and the increasing availability of these potent medications are facilitating improved patient outcomes. Together, these factors are fostering a more comprehensive approach to managing this chronic condition, thereby supporting the expansion of the market dedicated to ankylosing spondylitis care.

Restraints in the Global Ankylosing Spondylitis Market

The global ankylosing spondylitis market faces certain constraints due to the necessity for long-term management and ongoing treatment of the condition. Effective disease control heavily relies on patients' compliance with prescribed medication regimens, commitment to lifestyle modifications, and participation in regular follow-ups. These factors present various challenges, such as maintaining patient adherence and adjusting daily habits, which can ultimately affect the overall growth of the market. Furthermore, the complexities involved in monitoring the disease pose additional obstacles, highlighting the need for constant engagement and support for individuals living with ankylosing spondylitis.

Market Trends of the Global Ankylosing Spondylitis Market

The Global Ankylosing Spondylitis market is witnessing a significant trend towards prioritizing early diagnosis and treatment, driven by the recognition of its impact on patient outcomes. Increased awareness among healthcare providers and patient advocacy organizations is fostering educational initiatives that underscore the importance of timely detection and intervention. This proactive approach enables healthcare professionals to initiate appropriate therapies promptly, effectively managing inflammation and mitigating disease progression. The trend is likely to spur the demand for advanced diagnostic tools and innovative therapeutic solutions, ultimately contributing to enhanced quality of life for patients and expanding opportunities within the market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Ankylosing Spondylitis Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Non-Steroidal Anti Inflammatory Drug(NSAID)
• TNF Inhibitors
  • Humira
  • Simponi
  • Remicade
  • Enbrel
  • Cimzia
  • Other TNF Inhibitors
• Other Drug Classes

Global Ankylosing Spondylitis Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Others

Global Ankylosing Spondylitis Market Size & CAGR (2026-2033)

• North America (Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Therapeutics plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Izana Bioscience (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations